Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+, Mozilla Firefox 20+, Internet Explorer 11, Opera 15–18, Apple Safari 7, SeaMonkey 2.15-2.23

Become a member
  1. OncologyPRO
  2. Meeting Resources
  3. European Lung Cancer Congress 2023

ESMO Colloquium supported by Eli Lilly & Company - Precision oncology beyond EGFR/ALK for NSCLC in 2023: Test, target, manage

Current indications of precision therapeutics in advanced oncogene-addicted NSCLC beyond EGFR and ALK: Efficacy, safety, value

Date

30 Mar 2023

Session

ESMO Colloquium supported by Eli Lilly & Company - Precision oncology beyond EGFR/ALK for NSCLC in 2023: Test, target, manage

Topics

Tumour Site

Non-Small Cell Lung Cancer

Presenters

Benjamin Besse

Authors

B. Besse

Author affiliations

  • Institut Gustave Roussy, Villejuif/FR

Resources

This content is available to ESMO members and event participants.
Login

Resources from the same session

Q&A

Presenter: Solange Peters

Session: ESMO Colloquium supported by Eli Lilly & Company - Precision oncology beyond EGFR/ALK for NSCLC in 2023: Test, target, manage

Resources:

Webcast

Concluding remarks

Presenter: Benjamin Besse

Session: ESMO Colloquium supported by Eli Lilly & Company - Precision oncology beyond EGFR/ALK for NSCLC in 2023: Test, target, manage

Resources:

Webcast

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings

  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.